These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 674261)

  • 21. Evidence for interactions between central noradrenergic neurons and adrenal hormones in learning and memory.
    Roberts DC; Fibiger HC
    Pharmacol Biochem Behav; 1977 Sep; 7(3):191-4. PubMed ID: 200962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of neonatal 6-hydroxydopamine treatment on catecholamine levels and behavior during development and adulthood.
    Fobes JL; Olds ME
    Psychopharmacology (Berl); 1981; 73(1):27-30. PubMed ID: 6785785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical sympathectomy and two-way escape and avoidance learning in the rat.
    Lord BJ; King MG; Pfister HP
    J Comp Physiol Psychol; 1976 Mar; 90(3):303-16. PubMed ID: 932246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 6-Hydroxydopamine and avoidance: Possible role of response suppression.
    Lenard LG; Beer B
    Pharmacol Biochem Behav; 1975; 3(5):873-8. PubMed ID: 1208629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catecholamine-serotonin interaction effects on activity in rats neonatally treated with 6-hydroxydopamine.
    Olds ME; Fobes JL; Albert V
    Psychopharmacology (Berl); 1981; 73(1):31-3. PubMed ID: 6785786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Learning, brain noradrenaline and the pituitary--adrenal axis.
    Ogren SO; Fuxe K
    Med Biol; 1974 Dec; 52(6):399-405. PubMed ID: 4374613
    [No Abstract]   [Full Text] [Related]  

  • 27. Tolerance to p-chloroamphetamines effects on Sidman avoidance performance and catecholamine metabolism.
    Steranka LR; Sanders-Bush E; Barrett RJ
    Neuropharmacology; 1977 Nov; 16(11):761-9. PubMed ID: 22829
    [No Abstract]   [Full Text] [Related]  

  • 28. Catecholamine uptake sites in the rat heart after 6-hydroxydopamine treatment and in a genetically hypertensive strain.
    Salt PJ; Iversen LL
    Naunyn Schmiedebergs Arch Pharmacol; 1973; 279(4):381-6. PubMed ID: 4273713
    [No Abstract]   [Full Text] [Related]  

  • 29. Brain noradrenaline and the development of hypertension: the effect of treatment with central 6-hydroxydopamine or DSP-4.
    van den Buuse M; Versteeq DH; de Jong W
    Clin Exp Pharmacol Physiol; 1986 Jun; 13(6):469-76. PubMed ID: 3093124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neonatal 6-hydroxydopamine prevents adaptation to chemical disruption of the pituitary-adrenal system in the rat.
    Bialik RJ; Pappas BA; Roberts DC
    Horm Behav; 1984 Mar; 18(1):12-21. PubMed ID: 6323301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of intraperitoneal injection of 6-hydroxydopamine on the turnover and the levels of the brain catecholamines and the levels of plasma corticosterone in rats.
    Kawa A; Kamisaki T; Ariyama T; Kawabata T; Maeda Y; Okamoto O; Kanehisa T
    Clin Exp Pharmacol Physiol; 1979; 6(2):123-8. PubMed ID: 421367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neonatal sympathectomy by 6-hydroxydopamine in the rat: no effects on behavior by changes in endogenous brain norepinephrine.
    Pappas BA; Sobrian SK
    Life Sci I; 1972 Jul; 11(14):653-9. PubMed ID: 4656097
    [No Abstract]   [Full Text] [Related]  

  • 33. Reversal of the 6-hydroxydopamine-induced suppression of a CAR by drugs facilitating central catecholaminergic mechanisms.
    Ruiz M; Monti JM
    Pharmacology; 1975; 13(4):281-6. PubMed ID: 1187753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of intracisternal 6-hydroxydopamine treatment on acquisition and performance of rats in a double T-maze.
    Howard JL; Grant LD; Breese GR
    J Comp Physiol Psychol; 1974 Jun; 86(6):995-1007. PubMed ID: 4836849
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of catecholamine depleting drugs and d-amphetamine on self-stimulation of the substantia nigra and locus coeruleus.
    Cooper BR; Konkol RJ; Breese GR
    J Pharmacol Exp Ther; 1978 Mar; 204(3):592-605. PubMed ID: 24729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Learning impairment in rats after 6-hydroxydopamine-induced depletion of brain catecholamines.
    Mason ST; Iverson SD
    Nature; 1974 Apr; 248(5450):697-8. PubMed ID: 4151498
    [No Abstract]   [Full Text] [Related]  

  • 37. The impairment of learning of conditioned avoidance response in rats after 6-hydroxydopamine.
    Plech A; Herman ZS; Brus R; Drybanski A
    Act Nerv Super (Praha); 1975 Sep; 17(3):176-8. PubMed ID: 1199684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine.
    Cooper BR; Breese GR; Grant LD; Howard JL
    J Pharmacol Exp Ther; 1973 May; 185(2):358-70. PubMed ID: 4703827
    [No Abstract]   [Full Text] [Related]  

  • 39. Pituitary-adrenal activity and depletion of brain catecholamines after central administration of 6-hydroxydopamine.
    Kaplanski J; Smelik PG
    Res Commun Chem Pathol Pharmacol; 1973 Mar; 5(2):263-71. PubMed ID: 4699470
    [No Abstract]   [Full Text] [Related]  

  • 40. Modification of avoidance behavior in 6-hydroxydopamine-treated rats by stimulation of central noradrenergic and dopaminergic receptors.
    Lenard LG; Beer B
    Pharmacol Biochem Behav; 1975; 3(5):887-93. PubMed ID: 1208631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.